The US Trade Representative opened a Section 301 investigation into Germany on June 18, targeting what it calls systematic underpayment for innovative pharmaceutical products. The move represents a sharp escalation in an already tense transatlantic trade relationship, and it puts one of Europe’s most important export sectors squarely in the crosshairs.
What the investigation actually means
A Section 301 investigation is the US trade policy equivalent of loading a gun. It doesn’t fire tariffs immediately, but it creates the legal framework to do so. The USTR is now formally examining whether Germany’s pharmaceutical pricing policies constitute an unfair trade practice that harms American industry.
EU pharmaceutical exports to the US were valued at $127 billion in 2024, making the sector the single largest EU export category to America. Germany, with its outsized pharmaceutical industry anchored by companies like Bayer and Boehringer Ingelheim, accounts for a significant chunk of that figure and has historically run substantial trade surpluses with the US in this sector.
Proposed tariffs could reach up to 100% on certain patented products if US production is not prioritized.
